Insurance Coverage Changes: Patient Access and Practice Strategy Insurance coverage for GLP-1 therapies is increasingly volatile, with major PBMs and insurers announcing new restrictions and sudden mid-year formulary changes
Patients Lost 31LBS on Average In a trial with 1,387 patients who were obese but did not have Type 2 diabetes, patients were randomly assigned to different doses of Semaglutide
GP prescriptions of all forms of semaglutide (the active ingredient in Wegovy) are more stable, at around 130,000 items per month (including generics and products to treat diabetes)
Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism
Preventing joint injuries through balance training, fall prevention, and appropriate footwear is especially important in older adults. Managing metabolic health conditions such as diabetes and insulin resistance may also reduce osteoarthritis risk by limiting systemic inflammatory and metabolic stress on joint tissues, Baker said
Executive Summary Quick Insight: The GLP-1 Weight Loss Drug Market is on track to more than double to USD 192 billion by 2035 , driven by explosive patient demand for injectable and oral incretin therapies, multi-indication label expansion beyond obesity into cardiovascular protection and metabolic disease management, a robust late-stage pipeline of next-generation triple agonists, and unprecedented payer engagement transforming obesity into a fully reimbursable chronic disease requiring long-term pharmacological management